Invivyd Inc
NASDAQ:IVVD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Melhus Sparebank
OSE:MELG
|
NO |
|
S
|
Sanyu Co Ltd
TSE:5697
|
JP |
|
C
|
Copartner Technology Corp
TWSE:3550
|
TW |
|
Abdullah Al Othaim Markets CompanySJSC
SAU:4001
|
SA |
|
Fonet Bilgi Teknolojileri AS
IST:FONET.E
|
TR |
|
K
|
King Co Ltd
TSE:8118
|
JP |
|
Stemmer Imaging AG
XETRA:S9I
|
DE |
|
Phoenix Copper Ltd
LSE:PXC
|
VG |
|
I
|
InfoVision Optoelectronics Kunshan Co Ltd
SSE:688055
|
CN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
I
|
Invivyd Inc
NASDAQ:IVVD
|
482.2m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Invivyd Inc
Glance View
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered antibodies designed to provide neutralization across past and current SARS-CoV-2 variants of concern, including wildtype, Beta, Delta, and Omicron BA.1, BA.2, BA.5, and BA.2.75. The firm generates a pipeline of products for use in both the prevention and treatment of disease. Its advanced pipeline candidate includes adintrevimab, an investigational monoclonal antibody that is used against multiple variants of concern for the prevention and treatment of COVID-19. The firm also has multiple discovery stage candidates for the prevention of seasonal influenza.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Invivyd Inc is 93%, which is below its 3-year median of 93.6%.
Over the last 2 years, Invivyd Inc’s Gross Margin has decreased from 96.1% to 93%. During this period, it reached a low of 92.3% on Sep 30, 2024 and a high of 96.1% on Jun 30, 2024.
